TL;DR
This study reveals that common tetracycline antibiotics, even at low doses, can trigger Bacteroides dorei, a key gut bacterium, to produce previously unknown pro-inflammatory molecules called doreamides and N-acyladenosines. These metabolites can then activate host immune cells and potentially reshape the gut microbiome, offering a new perspective on how antibiotics interact with our internal microbial communities.
What Problem Does This Paper Address?
The human gut microbiome is a complex ecosystem where bacteria communicate and influence host health through secreted molecules, known as secondary metabolites. While we know these interactions are crucial, identifying the specific molecules and their functions has been challenging. This is partly because many of these "cryptic" metabolites are only produced under specific conditions, not typically found in standard lab cultures. Furthermore, the impact of common host-consumed substances, like FDA-approved drugs, on the production of these microbial metabolites and their subsequent effects on host physiology remains largely unexplored. This paper tackles this gap by investigating how Bacteroides dorei, a prevalent gut commensal, responds to a library of drugs, aiming to uncover new metabolites and understand their biological roles, particularly in the context of immune modulation.
Methods
The researchers employed a high-throughput elicitor screening (HiTES) approach, a powerful technique for discovering "cryptic" metabolites. This involved exposing Bacteroides dorei cultures to a library of 400 FDA-approved drugs. The cell-free supernatants were then analyzed using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-qTOF-MS) to identify and quantify metabolites whose production was significantly increased by the presence of a drug (elicitor). Once potential inducers were identified, the researchers used various spectroscopic methods, including 1D/2D NMR and HR-MS/MS, to elucidate the chemical structures of the newly discovered metabolites. To understand their biological function, they tested the immunogenic activity of these compounds using RAW 264.7 macrophages, assessing the expression of pro-inflammatory cytokines and antimicrobial peptides. They also investigated the biosynthetic pathways by culturing the bacteria with isotopically labeled amino acids and by analyzing the bacterial genome for relevant gene clusters.
Datasets
Not discussed in the paper. The study primarily relies on analyzing the metabolome of Bacteroides dorei in response to an external library of FDA-approved drugs.
Key Insights and Ideas
- Low-dose tetracyclines are potent inducers of cryptic metabolites: Surprisingly, common antibiotics like tetracyclines, even at sub-inhibitory concentrations, can significantly alter the metabolic output of gut bacteria, revealing previously hidden molecules.
- Discovery of novel immunomodulatory metabolites: The study identified six new serine-glycine dipeptide lipids (doreamides A-F) and two 6-N-acyladenosines produced by B. dorei. These are not just new molecules but have direct biological activity.
- Doreamides and N-acyladenosines are pro-inflammatory: These induced metabolites can activate host immune cells (macrophages), leading to the production of key pro-inflammatory cytokines like TNFα and IL-1β. This suggests a direct link between gut bacteria, drug intake, and host immune responses.
- Doreamides induce host antimicrobial peptide production: Beyond cytokine induction, doreamides also trigger the production of cathelicidin, a host-derived antimicrobial peptide. This adds another layer to how these bacterial metabolites can influence the gut environment.
- B. dorei's role in host defense during antibiotic treatment: The findings suggest that B. dorei, by producing these immunomodulatory molecules, might play a role in host defense and potentially reshape the gut microbiome during tetracycline therapy.
- The glsAB operon is conserved in Bacteroidota: The genes responsible for doreamide biosynthesis are widespread within the Bacteroidota phylum, indicating a conserved function for these metabolites across related bacteria.
Key Results
- Low-dose tetracyclines (e.g., demeclocycline) were identified as potent inducers of secondary metabolites in Bacteroides dorei.
- Six novel serine-glycine dipeptide lipids (doreamides A-F) and two 6-N-acyladenosines were structurally elucidated.
- The induced doreamides and N-acyladenosines upregulated pro-inflammatory cytokines (TNFα, IL-1β, IL-6, IL-10) and chemokines (MCP-1) in RAW 264.7 macrophages.
- Doreamides triggered significant induction of the antimicrobial peptide cathelicidin.
- Cathelicidin showed differential antimicrobial activity, being potent against several gut bacteria but not against B. dorei.
- The immunomodulatory effects of doreamides were found to be TLR2-dependent.
- The glsAB gene cluster, responsible for doreamide biosynthesis, is highly conserved within the Bacteroidota phylum.
Limitations and Future Work
The authors acknowledge that their study was conducted in vitro and therefore needs to be assessed further in animal models to confirm the observed effects in a more complex biological system. They also suggest that future studies should investigate whether other drugs or natural stressors (like bile acids or oxidative stress) can act as elicitors for B. dorei metabolites. Additionally, further research is needed to fully elucidate the regulatory pathways involved in tetracycline-induced doreamide biosynthesis and to determine if these metabolites have similar effects in other host cell types, such as intestinal epithelial cells and Paneth cells. The study also highlights the need for future work to explore the broader chemical space of the human microbiome, as many cryptic metabolites remain undiscovered.
Summary updated